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AbstrAct
Background: Epigenetic modifications have been shown to play an important 
role in the classification and pathogenesis of the pediatric brain tumor ependymoma, 
suggesting they are a potential therapeutic target.
Results: Agents targeting epigenetic modifications inhibited the growth and 
induced the death of ependymoma cells with variable efficiency. However, this was 
often not at clinically achievable doses. Additionally, DNA methylation profiling revealed 
a lack of similarity to primary ependymomas suggesting alterations were induced during 
culture. Toxicity to fetal neural stem cells was also seen at similar drug concentrations 
Conclusions: Agents targeting epigenetic modifications were able to inhibit the 
growth and induced the death of ependymoma cells grown in vitro. However, many 
agents were only active at high doses, outside clinical ranges, and also resulted in 
toxicity to normal brain cells. The lack of similarity in DNA methylation profiles between 
cultured cells and primary ependymomas questions the validity of using in vitro cultured 
cells for pre-clinical analysis of agents targeting epigenetic mechanisms and suggests 
further investigation using models that are more appropriate should be undertaken 
before agents are taken forward for clinical testing.
Materials and Methods: The effects of agents targeting epigenetic modifications on 
the growth and death of a panel of ependymoma cell lines was investigated, as well as 
toxicity to normal fetal neural stem cells. The ependymoma cell lines were characterized 
using DNA methylation profiling. 
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IntroductIon
Ependymoma is the second most common malignant 
pediatric tumor of the CNS, accounting for approximately 
10% of all brain tumors in children [1]. Prognosis remains 
relatively poor and little progress has been made in recent 
decades to develop new treatments. 
Epigenetic modifications can be defined as stable 
and heritable changes in gene expression resulting from 
modifications to the DNA molecule without alterations in 
the DNA sequence. Epigenetic alterations play a role in 
the development and progression of many cancers. The 
most common types of modification altered include DNA 
methylation, histone acetylation and histone methylation [2–5]. 
In cancer, increased DNA methylation at promoters 
of tumor suppressor genes, resulting in their silencing, is 
often seen. Therefore, de-methylating agents have been 
investigated for therapeutic use. One of the most advanced 
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is decitabine, which targets DNA methyltransferase 
enzymes. It has been approved by the Food and Drug 
Administration (FDA) for the treatment of myelodysplastic 
syndrome as well as being investigated in clinical trials for 
other cancers [6, 7]. 
Histone acetylation plays a key role in the 
regulation of gene expression and levels are often altered 
in cancer. Histone de-acetylase inhibitors (HDACi) are 
the most clinically advanced agents targeting epigenetic 
modifications. A number of agents targeting this 
modification are FDA approved, including vorinostat, 
for the treatment of cutaneous T-cell lymphoma, and 
panobinostat, for the treatment of multiple myeloma [8, 9].
Histone methylation also plays an important role in 
cancer development and progression [10]. In particular, 
the repressive tri-methylation mark on lysine 27 of histone 
H3 (H3K27) has been shown to be important for pediatric 
brain tumors including ependymoma [11, 12]. H3K27 is 
methylated by the polycomb repressor complex 2 (PRC2). 
Enhancer of zeste homolog 2 (EZH2), the catalytic subunit 
of PRC2, is commonly mutated or overexpressed in cancer 
[13]. Inhibitors targeting EZH2 have been developed 
including GSK343 and EPZ-6438 [14–16]. 
Recent studies have highlighted the importance of 
epigenetic modifications in ependymoma [11, 17–19]. 
DNA methylation profiling has demonstrated this 
epigenetic mark can define ependymoma sub-groups based 
on demographic and clinical features, including age at 
diagnosis and tumor location [11, 17]. For pediatric patients, 
DNA methylation defined two posterior fossa (PF) groups, 
EPN_PFA and EPN_PFB, and two supratentorial (ST) 
groups, EPN_RELPOS and EPN_YAP1. EPN_PFA tumors 
were shown to occur in young children and displayed a 
hyper-methylated phenotype. EPN_PFB tumors occurred in 
older children and displayed a hypo-methylated phenotype 
[11]. EPN_RELPOS and EPN_YAP1 ependymomas were 
characterized by recently discovered fusion genes involving 
RELA and YAP1 respectively [20].
Initial pre-clinical evidence supports the potential 
therapeutic targeting of epigenetic modifications in 
ependymoma.  Mack et al demonstrated decitabine and 
GSK343 inhibited the growth of primary ependymoma 
cultures in vitro. Studies also support the clinical potential 
of HDAC inhibitors in ependymoma [18, 21]. 
Pre-clinical analysis of agents targeting epigenetic 
modifications in ependymoma has so far been undertaken 
using a small set of in vitro cultured cells. However, the 
epigenetic profile of these models was not investigated. 
The clinical relevance of in vitro models has long been 
questioned and studies have shown that epigenetic 
modifications can alter during cell culture [22–24].
In this study, we have expanded the pre-clinical 
investigation of agents targeting DNA methylation, 
histone acetylation and H3K27 methylation using a 
panel of ependymoma cell lines. Alongside this, we used 
DNA methylation profiling to measure how closely the 
cultured cells retained their original profiles. We show 
that epigenetic agents inhibited the growth and induced the 
death of ependymoma cells with variable efficacy, but was 
often outside clinically achievable ranges. Importantly, 
DNA methylation profiling of the cultured ependymoma 
cells indicated their profiles were altered from that seen in 
primary ependymoma tumor tissue for the majority of the 
lines tested, questioning the validity of in vitro cultured 
cells for analysis of epigenetic agents. 
results
the majority of ependymoma cell lines did not 
closely resemble defined molecular groups
Cultured cells derived from six ependymomas (3 ST, 
3 PF) were used in the study. Analysis of C11orf95-RELA 
fusion status and DNA methylation profiling was used to 
characterize the cells.
C11orf95-RELA fusion status was determined using 
western blot to wild-type RELA. Fusions (seen as larger 
proteins than wild-type rela) were detected in all cells 
derived from ST ependymomas (BXD-1425EPN, DKFZ-
EP1, EPN1) but none of the PF cells (EPN8, EPN9, 
EPN10) (Figure 1A).
All cells underwent DNA methylation profiling 
using Infinium HumanMethylation450 BeadChip 
arrays (Illumina). Supervised class prediction by 
the previously published classifier [25] (http:// 
www.molecularneuropathology.org) was used to assign 
cell line profiles to tumor subgroups. The only cell line 
that could be confidently assigned to an ependymoma 
molecular subgroup was DKFZ-EP1, which was classified 
as EPN_RELPOS. EPN10 was classified as EPN_PFA. 
However, this was with a low level of confidence. All 
other ependymoma cells were misclassified with very low 
confidence scores (Table 1). DNA methylation has been 
shown to alter during in vitro cell culture, which may explain 
these discrepancies [22–24]. Clustering of the cultured 
ependymoma cells alongside ependymoma tumors, plus 
cell lines from other brain tumor types, demonstrated that 
all the cultured cells formed one group, with the exception 
of the DKFZ-EP1 cell line which correctly grouped with the 
EPN_RELPOS ependymomas (Figure 1B). This suggested 
that in vitro culture induced DNA methylation changes in 
the cells, resulting in a common culture induced profile. 
Agents targeting epigenetic modifications 
inhibited the growth of ependymoma cells
To assess the clinical potential of agents targeting 
epigenetic modifications, ependymoma cells were 
incubated with selected agents and the effects on cell 
viability investigated (Figure 2). For each agent there 
was no clear difference between the more representative 
model, DKFZ-EP1, and the other ependymoma cells. 
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There was also no clear difference between cells with 
(BXD-1425EPN, DKFZ-EP1, EPN1) or without (EPN8, 
EPN9, EPN10) the C11orf95-RELA fusion.
The HDAC inhibitors vorinostat and panobinostat 
were most effective, causing a significant decrease in 
viability in most cells tested (Figure 2A, 2B). IC50 
concentrations for vorinostat ranged from 5 µM to 
greater than 20 µM, and panobinostat from 90–510 nM 
(Supplementary Table 1).
The de-methylating agent decitabine caused a 
significant reduction in viability in BXD-1425EPN and 
EPN8 cells (Figure 2C), which was only seen after 144 
hrs. Only a modest effect on viability was seen in all other 
ependymoma cells tested. IC50 concentrations ranged 
from 50 nM to greater than 5 µM (Supplementary Table 1). 
The EZH2 inhibitor GSK343 did not induce a 
significant reduction in viability for the majority of 
ependymoma cells tested (Figure 2D). The largest effect 
was seen for BXD-1425EPN and EPN8 cells. IC50 
concentrations ranged from 16 µM to greater than 20 µM 
(Supplementary Table 1). The decrease in viability was 
only observed after 120 hrs. 
HDAC and EZH2 inhibition induced cell death
Cell death was analyzed to determine whether the 
epigenetic agents induced a cytotoxic response. One 
drug was selected targeting each epigenetic mechanism. 
Cell death was measured using a LDH assay following 
vorinostat, decitabine and GSK343 treatment (Figure 3). 
There was again no clear difference in the level of cell 
death induced between the more representative DKFZ-
EP1 cells and the other ependymoma cells, or between 
cells with or without the C11orf95-RELA fusion.
Vorinostat and GSK343 both induced cell death in 
ependymoma cells (Figure 3), suggesting this was the 
Figure 1: Cell line subgroup characterization. C11orf95-RELA fusion status was determined using western blot for wild-type rela 
(A). A larger protein than the wild-type (WT), representing the fusion gene, was seen in all three ST cell lines but not in the PF cells. t-SNE 
dimension reduction demonstrated that cultured ependymoma cells mainly grouped together with cell lines derived from other brain tumors 
rather than primary ependymoma samples, with the exception of DKFZ-EP1, which clustered with EPN_RELPOS cells (b).
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significant cause of decreased viability induced by both 
these agents. However, significant cell death was not 
induced by decitabine (Figure 3), suggesting a growth 
arrest was induced instead. 
Targeting multiple epigenetic mechanisms 
enhanced their inhibitory effects
The effect of targeting multiple epigenetic 
modifications was investigated to determine if a 
combinatorial approach enhanced their effects 
(Supplementary Figure 1). For combinations involving 
decitabine, cells were treated with decitabine alone before 
addition of the second drug. HDAC and EZH2 inhibitors 
can block the progression of G1 cells into S phase, which 
interferes with the action of decitabine [26, 27]. 
In general, no significant enhanced effects were seen 
between treatment with combinations or each drug alone 
(Supplementary Figure 1). No clear difference was seen in 
response to drug combinations between DKFZ-EP1 and 
other ependymoma cells tested.
Decitabine plus vorinostat showed some 
enhancement of effects in some cells tested. However, 
this was only seen at higher drug concentrations and was 
not seen in the DKFZ-EP1 cells. The combination of 
decitabine with GSK343 did not enhance their inhibitory 
Table 1: Cell Line subgroup classification from DNA methylation profiles
cell line Subgroup Prediction Prediction Score*
BXD-1425EPN CPC (high grade plexus tumor) 0.06
DKFZ-EP1 EPN_RELPOS 1.00
EPN1 MNG (meningioma) 0.07
EPN8 MNG (meningioma) 0.06
EPN9 MNG (meningioma) 0.07
EPN10 EPN_PFA 0.20
*0 = 0% confidence, 1 = 100% confidence.
Figure 2: Effect of epigenetic agents on ependymoma cell line viability. Epigenetic agents reduced the viability of ependymoma 
cells. Ependymoma cells were treated with vorinostat (A) and panobinostat (b), or vehicle control, for 72 hrs. Both agents reduced 
cell viability, relative to vehicle control, in the majority of ependymoma cells, including the DKFZ-EP1 cells. Ependymoma cells were 
incubated with decitabine (c) for 144 hrs. A decrease in viability was seen in only a minority of ependymoma cells, which did not include 
DKFZ-EP1 cells. Cells were incubated with GSK343 (d) for 120 hrs. GKS343 did not induce a decrease in viability in the majority of 
ependymoma cells tested. Cell viability was measured using a MTT assay.
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effects and for some combinations were antagonistic. 
Vorinostat combined with GSK343 enhanced the effects 
on cell viability in BXD-1425 and EPN1 cell lines, 
although in general only at higher concentrations.
HDAC and EZH2 inhibitors were toxic to 
normal cells
Fetal neural stem cells (fNSC) grown as 
multicellular spheroids were used to assess toxicity to 
normal cells. fNSCs were incubated with each drug using 
the same concentrations as ependymoma cells. The effect 
on cell viability was measured using an alamar blue assay.
All drugs reduced fNSC viability (Figure 4). The 
fNSCs were more sensitive to HDAC inhibitors and 
GSK343 than all ependymoma cells tested. However, 
they were less sensitive to decitabine than the most 
sensitive ependymoma cells (BXD-1425EPN, EPN8) 
(Supplementary Table 2).
dIscussIon
Recent research suggests epigenetic modifications 
play an important role in ependymoma pathology 
and are therefore a potential therapeutic target, which 
now needs testing using pre-clinical models. We have 
shown that agents targeting epigenetic modifications 
inhibited the growth of cultured ependymoma cells 
with variable efficiency, suggesting clinical potential in 
some instances. However, we also demonstrated a lack 
of similarity between the DNA methylation profiles of 
the majority of cultured ependymoma cell lines tested 
and primary ependymoma tumors, with cultured cells 
appearing closer to cell lines from other brain tumor 
types. This suggests alterations were induced during 
culture, resulting in a common DNA methylation profile 
that overrides the differences normally seen between 
these tumor types. DNA methylation has been shown to 
alter during cell culture [22–24] which may explain why 
the profiles of these cells did not match ependymoma 
tumors. 
These findings highlight the importance of profiling 
cell lines to measure their validity as a pre-clinical 
model, and questions the use of 2D cultured cells for 
pre-clinical testing of epigenetic agents, suggesting more 
representative models are needed. This might include 3D 
in vitro models. A number of 3D culture systems have 
been developed, including spheroids, organoids and 
growth on hydrogels or scaffolds, which allow cells to 
grow in a system that better reflects tissue architecture and 
physiological conditions [28, 29]. 3D models of various 
cancers, including brain tumors, have been shown to have 
Figure 3: Effect of epigenetic agents on ependymoma cell death. A LDH assay was used to measure whether cell death was induced 
by epigenetic agents. Vorinostat induced cell death in all ependymoma cells tested following 72 hrs treatment (A). Decitabine did not induce 
cell death in any ependymoma cells following treatment for 144 hrs (b). GSKS343 induced cell death following 120 hrs treatment (c).
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biological profiles closer to the primary tumor than cells 
cultured in 2D on a flat plastic surface [30–34].
No clear difference was seen in response to 
epigenetic agents between the one cell line, which retained 
an ependymoma-like DNA methylation profile (DFKZ-
EP1), and those that did not. However, as only one cell line 
was confidently assigned to an ependymoma subgroup, 
limited conclusions could be made about how much the 
alterations in DNA methylation seen during in vitro culture 
altered the response to the agents tested.
The most effective agents against ependymoma cells 
in this study were the HDAC inhibitors which induced 
cytotoxicity in the majority of ependymoma cells tested, 
including DKFZ-EP1, agreeing with previous reports 
[18, 21]. Milde et al also treated the DKFZ-EP1 cell 
line with vorinostat and panobinostat, identifying IC50 
concentrations of 776 nM and 2.9 nM respectively, which 
were lower than our calculated IC50 concentrations (5 µM 
and 360 nM). However, Milde et al treated the cells when 
grown as neurospheres instead of a monolayer in serum-
supplemented media, which could explain the difference 
in sensitivity. 
Although both vorinostat and panobinostat induced 
growth inhibition, it was not at clinically achievable 
concentrations. Reported peak plasma concentrations 
for vorinostat and panobinostat were 4.5 µM and 40 nM 
respectively [35, 36], with phase I trials of vorinostat in 
pediatric solid tumors suggesting this may be lower in 
pediatric patients (1.4–1.6 µM) [37, 38]. This suggests 
HDAC inhibitors would not be effective as single agents 
in patients and agrees with analysis of two HDAC 
inhibitors in an in vivo ependymoma mouse model where 
low activity was seen [39, 40]. Additionally, although 
vorinostat was well tolerated in phase I trials of pediatric 
solid tumors, including ependymoma, limited clinical 
responses were observed [37, 38]. A combination approach 
to lower doses needed for an effective response, or a local 
drug delivery system to enable effective concentrations 
to reach the tumor while avoiding high systematic doses, 
could improve the clinical potential of these agents. 
Previous research suggested DNA methylation plays 
an important role in ependymoma [11, 17, 19]. Growth 
inhibition was only achieved in two cell lines tested, 
which did not include DKFZ-EP1, questioning the clinical 
potential of this agent. Mack et al previously demonstrated 
growth inhibition of short-term cultures of cells derived 
from EPN_PFA tumors [11]. However, profiling was not 
undertaken to determine if the cells tested retained their 
original DNA methylation profile.
Where inhibition was achieved IC50 concentrations 
were within clinical ranges, with reported plasma 
concentrations up to 5 µM [41]. Decitabine has been 
shown to cross the blood brain barrier where CSF 
concentrations were reported at up to 50% of plasma 
concentrations [42]. Our results demonstrated the effects 
seen upon treatment with decitabine were cytostatic, 
suggesting it would need to be used in combination to 
induce cell death. 
The EZH2 inhibitor GSK343 was the least effective 
of all agents tested. Inhibition was achieved at relatively 
high concentrations compared to those identified 
previously in sensitive ependymomas [11]. However, 
it was closer to IC50 concentrations reported for other 
cancer types [16, 43]. Pharmacokinetic studies in rat 
Figure 4: Toxicity of epigenetic agents to fNSCs. Epigenetic agents displayed toxicity to fNSCs. Cells were incubated with each 
drug at the same concentrations and incubation times as ependymoma cells. Viability was measured using an alamar blue assay. 
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models demonstrated GSK343 displayed high clearance 
suggesting it is only useful as an in vitro experimental 
tool and not suitable for in vivo studies [16]. Alternative 
EZH2 inhibitors with good pharmacokinetic properties 
and clinical potential have now been developed, including 
EPZ-6438, which is currently being investigated in 
clinical trials with promising preliminary results [13–15]. 
However, initial pre-clinical testing suggested this drug 
also displayed low activity in ependymoma [44]. 
Multiple epigenetic mechanisms can be de-regulated 
in cancer and studies have shown benefit of targeting 
multiple mechanisms in combination [45, 46]. However, 
the combinations tested against ependymoma cells did not 
show a significant increase in the effects on cell viability.
Epigenetic modifications play a key role in normal 
brain development [47, 48]. Therefore, caution must 
be taken when considering targeting these processes for 
ependymoma therapy. Our analysis suggested the drugs 
we tested do show toxicity to normal neural stem cells 
at similar or lower concentrations than those required to 
inhibit ependymoma cell growth. However, the fetal brain 
has been shown to have the capacity to respond and repair 
damage induced by the de-methylating agent 5-azacytidine 
[49]. Studies investigating toxicity to normal astrocytes 
and neuronal cells suggest decitabine was not toxic to these 
cells at concentrations that inhibited growth in sensitive 
ependymoma cell lines [50, 51]. In contrast, vorinostat and 
panobinostat have been shown to induce cytotoxicity to 
normal astrocytes and neurons at similar concentrations 
to those needed to inhibit ependymoma cell growth 
[52–54]. However, no neurotoxicity was seen following 
systematic administration of vorinostat to mice [55], or in 
a recent human trial of vorinostat in recurrent glioblastoma 
[56]. Additionally, in clinical trials of pediatric patients, 
epigenetic drugs have been well tolerated [37, 38, 57, 58]. 
Further analysis is needed to determine the long-term 
consequences of any toxicity induced. 
In conclusion, we have presented pre-clinical 
evidence demonstrating epigenetic agents could inhibit the 
growth of ependymoma cells. However, our results suggest 
caution is needed in the clinical progression of these 
agents as inhibitory effects were not always at clinically 
achievable concentrations and toxicity to normal cells was 
also seen. Importantly, the alteration of DNA methylation 
profiles in the majority of cells tested questions the validity 
of using 2D in vitro cultured cell lines as a model and 
suggests we need more accurate and biologically relevant 
models for pre-clinical testing to identify successful drug 
combinations before translation into the clinical setting.
MAterIAls And Methods
Cell culture
The ependymoma cell line BXD-1425EPN 
was provided by Dr Xiao-Nan Li, Baylor College 
of Medicine and has previously been characterized 
[59]. Cells were derived from a 9-year-old male 
with a recurrent ST anaplastic ependymoma. The 
DKFZ-EP1 cell line was provided by Dr T Milde and 
Dr O Witt, DKFZ and has previously been characterized 
[21]. Cells were derived from the malignant ascites of 
an 18-year-old female with a primary grade III classic 
ST ependymoma. The EPN1 cell line was generated and 
characterized in house [60]. Cells were derived from a 
13-year-old male with a recurrent ST ependymoma. Short 
term cultures of three PF ependymomas were established 
as previously described [60]. EPN8 was derived from 
a 1.5-year-old male with a primary grade III anaplastic 
PF ependymoma. EPN9 was derived from a 16-month 
female with a primary grade II PF ependymoma. EPN10 
was derived from a 2-year-old female with a PF primary 
anaplastic ependymoma. 
Cells were cultured in standard humidified incubators 
at 5% CO2. BXD-1425EPN and DKFZ-EP1 cells were 
cultured in DMEM (Invitrogen) supplemented with 
10% fetal bovine serum (FBS) (PAA Laboratories) plus 
antibiotics. EPN1, EPN8, EPN9 and EPN10 were cultured 
in DMEM supplemented with 15% FBS plus antibiotics.
Doubling times for the cell lines were calculated 
as BXD-1425EPN; 23 hrs, DKFZ-EP1; 116 hrs, EPN1; 
203 hrs, EPN8; 48 hrs, EPN9; 34 hrs, EPN10; 48 hrs. The 
passage range for the cell lines used were BXD-1425EPN; 
P66-75, DKFZ-EP1; P10-25, EPN8; p6-15, EPN9; p6-15, 
EPN10 p6-15.
Cell line authentication
STR DNA profiling analysis was used for cell 
line authentication by Eurofins Genomics (Ebersberg, 
Germany). STR genotypes were generated for two 
different passages of each line and, where available, the 
DNA extracted from the tumor tissue the cell line was 
derived from. Genotypes for all passages of each line 
matched each other. The genotypes of the primary lines 
EPN1, EPN8 and EPN10 matched the primary tissue they 
were derived from, confirming the cultured cells originated 
from the tumor. No cell line matched any profile in the 
ATCC and DSMZ databases.
Determination of C11orf95–rela fusion status
Ependymoma cells were analyzed for the presence 
of the C11orf95-RELA fusion using western blot of wild-
type RELA [20]. Western blots were run as previously 
described [61]. Membranes were incubated with 
primary antibodies to RELA (1/10,000, Cell Signalling 
Technology) and GAPDH (1/50,000, Abcam).
dnA methylation analysis
DNA was extracted from cells as previously described 
[19]. Profiling was performed on bisulphite modified 
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DNA using Infinium HumanMethylation450 BeadChip 
arrays (Illumina) at UCL Genomics (London, UK). 
All computational analyses were performed in R version 
3.4.1 [62]. Raw signal intensities were obtained from IDAT 
files using the minfi Bioconductor package [63]. Each sample 
was normalized by performing a background correction 
(shifting 5% percentile of negative control probes to 0) and 
a dye-bias correction for both color channels. A correction 
for the type of material used (FFPE/frozen) was performed 
by fitting univariate, linear models to the log2-transformed 
intensity values (removeBatchEffect function, limma 
package v3.34.5 [64]). Methylated and un-methylated signals 
were corrected individually. Beta values were calculated 
from the re-transformed intensities using an offset of 100. 
Prior to clustering probes targeting the X and Y 
chromosomes, probes containing a single nucleotide 
polymorphism within five base pairs of, and including, the 
target CpG and probes not mapping uniquely to the human 
reference genome (hg19) were removed. To perform 
unsupervised dimension reduction the remaining probes 
were used to calculate the 1-variance weighted pearson 
correlation between samples. The resulting matrix was 
used for input for t-SNE analysis (t-Distributed Stochastic 
Neighbor Embedding [65], Rtsne package version 0.13 
[66]) with the default parameters: theta = 0, pca = F, 
max_iter = 2500, perplexity = 30.
To predict tumor subgroups a methylation 
based classifier was used [25] (http://www.
molecularneuropathology.org) which assigns methylation 
profiles to 91 different tumor subgroups including all 
ependymoma subgroups previously described [17] and 
gives a confidences score for the prediction.
Ependymoma cell line methylation profiles have 
been deposited in NCBI’s Gene Expression Omnibus 
(GEO http://www.ncbi.nlm.nih.gov/geo) and are accessible 
through GEO Series accession number GSE111428. 
Methylation data of ependymomas used for the t-SNE 
analysis are available in GEO series GSE65362. Methylation 
data for medulloblastoma and high grade glioma cell lines 
used for the t-SNE analysis area available in GEO series 
GSE112067. The medulloblastoma cell lines used were 
DAOY, UW228-2, ONS-76, D425 MED, D458 MED and 
D487 MED. The high grade glioma cell lines used were SJ-
G2 and SF188. All were cultured under standard conditions 
prior to DNA extraction and methylation profiling. 
Drugs
All drugs were reconstituted in DMSO. Decitabine 
(Sigma-Aldrich) at a concentration of 200 mM, vorinostat 
(Sigma-Aldrich) 250 mM, panobinostat (Selleck 
Chemicals) 50 mM and GSK343 (Sigma-Aldrich) 28 mM.
MTT viability assay
Cells were seeded in 96 well plates and incubated 
overnight. Subsequently, cells were treated with indicated 
drug or vehicle control (DMSO). For vorinostat, viability 
was measured after 72 hrs exposure to the drug. For 
GSK343, drug was replenished after 72 hrs and viability 
measured 120 hrs after drug treatment started. Cells were 
treated with decitabine using similar methods to published 
studies [67–70]. Transient low doses that induce de-
methylation but no cytotoxicity, that was unrelated to DNA 
methylation, were used. Decitabine was replenished 24 
and 48 hrs after initial treatment. Viability was measured 
144 hrs after drug treatment started.
For combination experiments targeting multiple 
epigenetic modifications, drugs were used at a fixed ratio 
based on single agent IC50 concentrations. Cells were 
treated with 0.125, 0.25, 0.5, 1, 2 and 4 times the IC50 
concentration. For combinations involving decitabine, 
cells were pre-treated for 48 hrs with decitabine before 
addition of the second drug after which cells were 
incubated for a further 96 hrs. Cells were incubated with 
vorinostat in combination with GSK343 for 72 hrs.  
Cell viability was measured using the Cell 
proliferation kit I (MTT) (Roche), following 
manufacturer’s instructions. Each condition was performed 
in triplicate, in three independent repeats. The percentage 
of viable cells relative to vehicle control was calculated 
based on averaged triplicates for each condition. IC50 
concentrations were estimated from dose response curves. 
ldh assay
Cells were seeded in 96 well plates and incubated 
overnight. Subsequently, cells were treated with indicated 
drug or vehicle control. Cells were incubated for 72 hrs with 
vorinostat, 120 hrs with GSK343 and 144 hrs with decitabine 
before analysis. GSK343 was replenished after 72 hrs and 
decitabine after 24 and 48 hrs. Cell death was measured 
using the Cytotoxicity Detection KitPLUS (LDH) (Roche), 
following manufacturer’s instructions. Each condition was 
performed in triplicate, in three independent repeats. 
Toxicity analysis
Fetal neural stem cells (fNSC) were derived and 
cultured as previously described [71]. 10,000 cells per 
well were seeded into Ultra low attachment 96-well 
round bottom plates and incubated for 48 hrs, allowing 
time for formation of a single uniformly sized spheroid. 
Subsequently, indicated drug or vehicle control was added 
and incubated for indicated time period. Decitabine was 
replenished after 24 and 48 hrs. Cell viability was measured 
using an alamar blue assay (ThermoFisher Scientific), 
following manufacturer’s instructions. Each condition was 
performed in triplicate, in three independent repeats.
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